SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma gets USFDA’s final nod for Topiramate Extended-Release Capsules

30 Aug 2023 Evaluate

Ajanta Pharma has received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg and 200 mg. Topiramate is the generic version of Supernus Pharmaceuticals Inc’s Trokendi XR. As per the settlement with the innovator, Ajanta can launch Topiramate on February 1, 2026 or earlier under certain circumstances. 

The company has received 50 final ANDA approvals, out of which 41 are commercialized. Ajanta also holds 2 tentative approvals and 22 ANDAs are awaiting USFDA approvals. 

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.

Ajanta Pharma Share Price

3090.95 26.00 (0.85%)
12-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1845.90
Dr. Reddys Lab 1270.10
Cipla 1292.00
Zydus Lifesciences 930.75
Lupin 2246.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×